Atherogenesis – tried and tested pieces in the puzzle

Rüdiger E. Scharf

doi:10.1055/s-0037-1616861

Hämostaseologie, Inhaltsverzeichnis

Hamostaseologie 2016; 36(02): 73-74
DOI: 10.1055/s-0037-1616861

Editorial

Schattauer GmbH

Atherogenesis – tried and tested pieces in the puzzle

Rüdiger E. Scharf

¹Dept. of Experimental and Clinical Hemostasis, Hemotherapy and Transfusion Medicine, Heinrich Heine University Medical Center, Düsseldorf

²Hemophilia Comprehensive Care Center, Heinrich Heine University Medical Center, Düsseldorf

³Biological Medical Research Center, Heinrich Heine University, Düsseldorf

References
1 Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-126.
2 Weber C, Hristov M. Atherogenesis and inflammation. From cellular mediators to regulatory mechanisms of inflammation in atherosclerosis. Hämostaseologie 2015; 35: 99-101.
3 Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nature Med 2011; 17: 1410-1422.
4 Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002; 91: 281-291.
5 Tabas I, Bornfeldt KE. Macrophage phenotype and function in different stages of atherosclerosis. Circ Res 2016; 118: 653-667.
6 Libby P, Lichtman AH, Hansson GK. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity 2013; 38: 1092-1104.
7 Schiopu A, Frendeus B, Jansson B. et al. Recombinant antibodies to an oxidized low-density lipo-protein epitope induce rapid regression of atherosclerosis in apobec-1(-/-)/low-density lipoprotein receptor(-/-) mice. J Am Coll Cardiol 2007; 50: 2313-2318.
8 Badrnya S, Butler LM, Soderberg-Naucler C, Volf I, Assinger A. Platelets directly enhance neutrophil transmigration in response to oxidised low-density lipoprotein. Thromb Haemost 2012; 108: 719-729.
9 Birukov KG. Cyclic stretch, reactive oxygen species, and vascular remodeling. Antioxid Redox Signal 2009; 11: 1651-1667.
10 Scharf RE. Platelet pathology and vascular medicine. Hämostaseologie 2015; 35: 9.
11 Scharf RE. Von Willebrand factor, hemostasis and inflammation. Hämostaseologie 2015; 35: 209-210.
12 Scharf RE. Coagulation disorders. Recent lessons from clinical conditions. Hämostaseologie 2015; 35: 301-302.
13 Scharf RE. Platelet pathology and antiplatelet strategies. Resolved and unresolved issues. Hämostaseologie 2016; 36: 7-8.
14 Sun Q-A, Runge MS, Madamanchi NR. Oxidative stress, NADPH oxidases, and arteries. Hämostaseologie 2016; 36: 77-88.
15 Bartolini-Gritti B, Binder CJ. Oxidation-specific epitopes are major targets of innate immunity in atherothrombosis. Hämostaseologie 2016; 36: 89-96.
16 Weber C, Döring Y, Noels H. Potential cell-specific functions of CXCR4 in atherosclerosis. Hämostaseologie 2016; 36: 97-102.
17 Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link?. Kidney Int 2001; 59: 407-414.
18 Andrassy K. Kidney and haemostasis. A (personal) time-journey. Hämostaseologie 2015; 35: 73-76.
19 Harenberg J, Hentschel VA, Du S. et al. Anticoagulation in patients with impaired renal function and with haemodialysis. Anticoagulant effects, efficacy, safety, therapeutic options. Hämostaseologie 2015; 35: 77-83.
20 Bauer A, Limperger V, Nowak-Göttl U. End-stage renal disease and thrombophilia. Hämostaseologie 2016; 36: 103-107.
21 Kurnik K, Bidlingmaier C, Hütker S, Olivieri M. Haemostatic disorders in children. Hämostaseologie 2016; 36: 109-125.